GEN Edge - GEN - Genetic Engineering and Biotechnology News

Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting

Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting

Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data

Artificial Intelligence

Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data

FDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene Therapy

FDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene Therapy

FDA Delays PDUFA Action on Agios’ Mitapivat sNDA for SCD

FDA Delays PDUFA Action on Agios’ Mitapivat sNDA for SCD

StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance

StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance

Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die

Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die

Anthropic IPO Discloses Plans for Life Sciences Growth

Artificial Intelligence

Anthropic IPO Discloses Plans for Life Sciences Growth

StockWatch: Investment Banker Talks U.S.-Chinese Deals, IPOs, and a Tough Climate for Startups Seeking Capital

StockWatch: Investment Banker Talks U.S.-Chinese Deals, IPOs, and a Tough Climate for Startups Seeking Capital

EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private

EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private

Nvidia, UW Institute for Protein Design Unveil Open-Source Protein Design AI Model

Artificial Intelligence

Nvidia, UW Institute for Protein Design Unveil Open-Source Protein Design AI Model

Roche, Hansoh Launch Up-to-$15B+ Cancer ADC Collaboration

Roche, Hansoh Launch Up-to-$15B+ Cancer ADC Collaboration

StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics

StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics

Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data

Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data

UCB Dedicates Future U.S. Biologics Manufacturing Campus in Georgia

UCB Dedicates Future U.S. Biologics Manufacturing Campus in Georgia

StockWatch: Caribou Plunges as It Pursues Strategic Alternatives

StockWatch: Caribou Plunges as It Pursues Strategic Alternatives

Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition

Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition

Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue

Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue

StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit

StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit

Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs

Artificial Intelligence

Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs

StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day

StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day

Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders

Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders